摘要
目的评价雷帕霉素联合碘-125(I125)治疗中晚期非小细胞肺癌(NSCLC)的临床疗效。方法 92例NSCLC患者随机分为对照组和试验组,每组46例,对照组按照粒子植入治疗计划系统(TPS)制定粒子治疗计划,在电子计算机断层扫描(CT)引导下将I125植入肿瘤内,处方剂量为90 Gy。试验组在此基础上加用雷帕霉素,每次2 mg,每天1次,3周为1个疗程,治疗4个疗程。治疗结束后4周进行CT扫描,参照实体瘤疗效评价标准(RECIST)进行疗效评价;观察并记录患者治疗后的卡式体能状态评分(KPS)、体重指数(BMI)和疾病进展时间(TTP);记录2组的生存期和不良反应。结果试验组客观缓解率(43.48%)显著高于对照组(30.43%,P<0.05);2组患者治疗后KPS、BMI和TTP较治疗前升高(P<0.01,P<0.05,P<0.01),试验组治疗后上述指标显著高于对照组(P<0.05,P<0.01,P<0.05);试验组中位生存时间为17.03个月,1年生存率为74.52%,显著高于对照组的13.16个月和63.35%(P<0.05)。2组患者在胃肠道不适、肝肾功能损伤、贫血等方面差异无统计学意义(P>0.05)。结论雷帕霉素联合I125粒子植入联合应用,能有效提高中晚期NSCLC患者的疗效,提高患者KPS、BMI及TTP水平,延长患者生存时间,不良反应少。
Objective To evaluate the clinical effect on rapamycin combined with iodine- 125 in the treatment of advanced non- small cell lung cancer. Methods A total of 92 patients with advanced non- small cell lung cancer were randomly divided into control group（ 46 cases） and treatment group（ 46 cases）. The iodine 125 particle implantation was performed according to the treatment planning system（ TPS） formulation by CT guided and the dosage was 90 Gy. The treatment group were treated with rapamycin（ 2 mg per time,qd） on the basis of control group.Three weeks is one course,patients all treated for four courses. The evaluation of treatment effect was confirmed by CT scans after the four courses of treatment. The efficacy was evaluated by response evaluation criteria in solid tumors reference（ RECIST） criteria. The changes of KPS,BMI and TTP were recorded and the survival time, adverse reactions were compared between the two groups. Results The objective response rate was 43. 48% in the treatment group,significantly higherthan that in control group,which was 30. 43%（ P〈0. 05）. The KPS,BMI and TTP of the two groups increased than before treatment,and treatment group was more significant（ P〈0. 05,P〈0. 01）. The median survival time（ 17. 03months） and one year survival rate（ 74. 52%） in treatment group were higher than those in control group（ 13. 16 months,63. 35%,P〈0. 05）. The adverse reactions of gastrointestinal tract,liver and kidney dysfunction and anemia in the two groups had no statistical differences（ P〉0. 05）. Conclusion Rapamycin combined with iodine- 125 can improve the clinical effects of advanced non- small cell lung cancer and improve the levels of KPS,BMI and TTP,and also extend the survival period of patient and decrease adverse reactions.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2015年第19期1922-1924,共3页
The Chinese Journal of Clinical Pharmacology
关键词
雷帕霉素
碘-125
非小细胞肺癌
联合应用
临床研究
rapamycin
iodine-125
non-small cell lung cancer
combined application
clinical research
